Authorization

HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics' Gout Discovery Pipeline

Fifth Milestone Achieved by HemoShear with Novel Compounds for Second TargetCHARLOTTESVILLE, Va., Sept. 21, 2022 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fifth payment that HemoShear has earned in accordance with the Horizon exclusive drug discovery agreement established in January 2019.By combining Horizon's expertise in gout with HemoShear's drug discovery capabilities, we are breaking new ground "In three years, HemoShear has identified two novel therapeutic targets and generated lead compounds for these two completely different strategies to potentially treat gout," said Robert Stoffel, PhD, vice president, research at Horizon. "Gout is often associated with elevated uric acid levels and data from the REVEAL-Txa?? platform indicates that these programs have the potential to lower uric acid levels. We look forward to the ongoing work on potential candidates selective to a second target.""By combining Horizon's expertise in gout with HemoShear's drug discovery capabilities, we are breaking new ground with the early stage characterization of two novel potential approaches to lowering uric acid levels," said Ryan Feaver, PhD, executive director and head of exploratory biology at HemoShear. "Our REVEAL-Txa?? drug discovery platform has been a key factor in achieving this milestone and in the success of the collaboration, aimed at delivering first-in-class modulators for both programs."Under the terms of the agreement, HemoShear received an upfront payment and R&D funding, and Horizon received exclusive access to HemoShear's proprietary disease modeling platform, to discover potential new therapeutics for gout. Successful development and commercialization of multiple therapies by Horizon would make HemoShear eligible to receive milestone payments of potentially more than $500 million plus royalties. Further financial terms were not disclosed.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2022    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
282930